Pegcetacoplan (APL-2) in Neovascular AMD

Part of paid clinical trials in Beverly Hills, California.

Sponsor
Apellis Pharmaceuticals, Inc.
Study ID
NCT03465709
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Neovascular Age-related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD

Key Dates

Start date
Feb 14, 2018
Status verified
Sep 2020
Primary completion
Apr 5, 2019
Completion
Apr 5, 2019

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pegcetacoplan Study Drug

Primary Outcome Measure

Number of Subjects Experiencing Ocular and Systemic Treatment-Emergent Adverse Events (TEAEs) Including by Maximum Severity [ Time Frame: Day 1 up to end of study (up to 1 year). ]

Locations (4)

FacilityCityStateZIPSite coordinators
Apellis Clinical SiteBeverly HillsCalifornia90211-
Apellis Clinical SiteHagerstownMaryland21740-
Apellis Clinical SiteClevelandOhio44122-
Apellis Clinical SiteHoustonTexas77030-

Find similar trials in Beverly Hills, CA

By research site
Apellis Clinical Site· Beverly Hills, CAApellis Clinical Site· Hagerstown, MDApellis Clinical Site· Cleveland, OHApellis Clinical Site· Houston, TX

Related Studies